Copy Number Aberrations of Multiple Genes Identified as Prognostic Markers for Extrahepatic Metastasis-free Survival of Patients with Hepatocellular Carcinoma

Abstract

Extrahepatic metastasis confers unfavorable patient prognosis in patients with hepatocellular carcinoma (HCC), however, reliable markers allowing prediction of extrahepatic metastasis at the time of initial diagnosis are still lacking. This study was to identify gene-level copy number aberrations (CNAs) related to extrahepatic metastasis-free survival of HCC patients, and further examine the associations between CNAs and gene expression. Array comparative genomic hybridization (aCGH) and expression array were used to analyze gene CNAs and expression levels, respectively. The associations between CNAs of a panel of 20 genes and extrahepatic metastasis-free survival were analyzed in 66 patients with follow-up period of 1.6–90.5 months. The gene expression levels between HCCs with and without gene CNA were compared in 109 patients with HCC. We observed that gains at MDM4 and BCL2L1, and losses at APC and FBXW7 were independent prognostic markers for extrahepatic metastasis-free survival of HCC patients. Integration analysis of aCGH and expression data showed that MDM4 and BCL2L1 were significantly upregulated in HCCs with gene gain, while APC and FBXW7 were significantly downregulated in HCCs with gene loss. We concluded that gene gains at MDM4 and BCL2L1, and losses at APC and FBXW7, with concordant expression changes, were associated with extrahepatic metastasis-free survival of HCC patients and have potential to act as novel prognostic markers.

Keywords

hepatocellular carcinoma / extrahepatic metastasis-free survival / gene / copy number aberration / expression

References

[1] SiegelRL, MillerKD, JemalA. Cancer Statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30

[2] ChenW, ZhengR, BaadePD, et al.. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132

[3] PinkelD, AlbertsonDG. Array comparative genomic hybridization and its applications in cancer. Nat Genet, 2005, 37(Suppl): S11-17

[4] BeroukhimR, MermelCH, PorterD, et al.. The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463(7283): 899-905

[5] AliH, BitarMS, Al MadhounA, et al.. Functionally-focused algorithmic analysis of high resolution microarray-CGH genomic landscapes demonstrates comparable genomic copy number aberrations in MSI and MSS sporadic colorectal cancer. PLoS One, 2017, 12(2): e0171690

[6] WangP, ShanL, XueL, et al.. Genome wide copy number analyses of superficial esophageal squamous cell carcinoma with and without metastasis. Oncotarget, 2017, 8(3): 5069-5080

[7] CastagnolaP, ZoppoliG, GandolfoS, et al.. Genomic DNA Copy Number Aberrations, Histological Diagnosis, Oral Subsite and Aneuploidy in OPMDs/OSCCs. PLoS One, 2015, 10(11): e0142294

[8] QiLN, LiLQ, ChenYY, et al.. Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China. PLoS One, 2013, 8(12): e83465

[9] WangD, ZhuZZ, JiangH, et al.. Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma. Hepatol Int, 2015, 9(3): 438-446

[10] ChenL, ZhuZZ, LiuSF, et al.. Loss at 16q22.1 identified as a risk factor for intrahepatic recurrence in hepatocellular carcinoma and screening of differentially expressed genes. Neoplasma, 2016, 63(1): 114-120

[11] ZhaoK, ZhaoY, ZhuJY, et al.. A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma. Curr Med Sci, 2018, 38(4): 590-596

[12] FurutaM, UenoM, FujimotoA, et al.. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol, 2017, 66(2): 363-373

[13] MarkeyMP. Regulation of MDM4. Front Biosci (Landmark Ed), 2011, 16: 1144-1156

[14] RiemenschneiderMJ, KnobbeCB, ReifenbergerG. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer, 2003, 104(6): 752-757

[15] AchT, Schwarz-FurlanS, AchS, et al.. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. J Oral Pathol Med, 2016, 45(7): 500-509

[16] WatanabeJ, KushihataF, HondaK, et al.. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery, 2004, 135(6): 604-612

[17] Karczmarek-BorowskaB, FilipA, WojcierowskiJ, et al.. Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer, 2006, 51(1): 61-69

[18] EspanaL, FernandezY, RubioN, et al.. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res Treat, 2004, 87(1): 33-44

[19] ZhangH, XueJ, HesslerP, et al.. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer, 2015, 14: 126

[20] SmithLT, MayersonJ, NowakNJ, et al.. 20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer, 2006, 45(10): 957-966

[21] MasudaM, SawaM, YamadaT. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer. Pharmacol Ther, 2015, 156: 1-9

[22] Debouki-JoudiS, TrifaF, KhabirA, et al.. CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients. Cancer Biomark, 2017, 18(2): 133-141

[23] FangZ, XiongY, LiJ, et al.. Detection of APC gene deletions in colorectal malignancies using quantitative PCR in a Chinese population. Pathol Oncol Res, 2011, 17(3): 657-661

[24] CaoJ, GeMH, LingZQ. Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis. Medicine (Baltimore), 2016, 95(7): e2496

[25] WangX, ZhangJ, ZhouL, et al.. Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway. Int J Oncol, 2015, 47(1): 231-243

[26] YokoboriT, MimoriK, IwatsukiM, et al.. Copy number loss of FBXW7 is related to gene expression and poor prognosis in esophageal squamous cell carcinoma. Int J Oncol, 2012, 41(1): 253-259

[27] SionovRV, NetzerE, ShaulianE. Differential regulation of FBXW7 isoforms by various stress stimuli. Cell Cycle, 2013, 12(22): 3547-3554

[28] DavisRJ, WelckerM, ClurmanBE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell, 2014, 26(4): 455-464

[29] AkhoondiS, LindstromL, WidschwendterM, et al.. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res, 2010, 12(6): R105

[30] GaoQ, ZhangJ, LiuJ. Pathological analysis of colorectal cancer complicated with primary hypertension. Mod Pract Med (Chinese), 2013, 29(8): 1268-1270

[31] KimSA, MoonH, RohJL, et al.. Postdiagnostic use of beta-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up. Clin Transl Oncol, 2017, 19(7): 826-833